Skip to main content

Advertisement

Table 2 Toxicities

From: FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

  No. of Patients (%)  
  Grade 1 Grade 2 Grade 3 Grade 4
Hematologic event     
Neutropenia 2 (7.4) 3 (11.1) 2 (7.4) 0 (0.0)
Febrile neutropenia - - 0 (0.0) 0 (0.0)
Thrombocytopenia 12 (44.4) 1 (3.7) 3 (11.1) 0 (0.0)
Anemia 10 (37.0) 5 (18.5) 2 (7.4) 0 (0.0)
Nonhematologic event     
Asthenia 7 (25.9) 11 (40.7) 4 (14.8) 0 (0.0)
Nausea/Vomiting 10 (37.0) 6 (22.2) 0 (0.0) 0 (0.0)
Mucitis 3 (11.1) 0 (0.0) 0 (0.0) 0 (0.0)
Diarrhea 6 (22.2) 4 (14.8) 0 (0.0) 0 (0.0)
Sensory neuropathy 10 (37.0) 2 (7.4) 2 (7.4) 0 (0.0)
  1. Toxicities were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0).